Our live Investing Matters Podcast Special which took place at the Master Investor Show discussing 'How undervalued is the UK stock market?', has just been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
All FUM's 'clever' wordplay over patents that confuses investors and 'experts' like Liberum is likely to come back to bite them in the posterior. Any potential partner will have patent lawyers who will see through such 'gameplay' and could make FUM manangement look tricksy & not to be trusted. The one thing you need in a successful negotiation is trust and clever tricks don't fool anyone.... although ananda & Liberum are more gullible than most.
'Experts' aint what they used to be.
"Futura’s patent protection on MED3000 expires in 2028 however the company has filed for additional patent protection that, if granted,...."
======================
More dodgy information from his 'expert' source, no doubt (Liberum). It just aint true. Clever word play by FUM that presumably Liberum have accepted without questioning. The Fact is that MED3000 doesn't have a patent...it's pending. The patents FUM do have are for the GTN products (MED2002/2005) and I don't know if they are anything to do with MED3000. Those patents are probably worthless. The new MED3000 patent is what's important....and it is patent pending. The unvarnished truth. Sorry about that.
Frank, all valid points. I would hope that FUM are investigating how MED3000 actually works...such knowledge may allow them to enhance the effectiveness of MED3000 (or MED3001). It may also give any potential partner that they are investing in something with scientific rigour (and not the 'pig in a poke' how ananda described it).
BTW 'volatile solvent components specifically tailored' = "mixture of herbs & spices"
Isn't Kentucky fried chicken coating a secret "mixture of herbs & spices". No one ingredient is presumably that unique but the ratio & nature of those ingredients creates something special & 'valuable'. Using modern mass spectometer (or other modern tech) it is probably fairly easy to deconstruct a compound, change it slightly and create your own version. Assuming it is worth the effort....I expect Pfizer have the resources!!
The patent has not been made public yet so we can only speculate about the content, which is a pointless exercise. FUM probably knows or is investigating the mechanism in depth, beyond their mentions of evaporative effect. FUM won't make it public before the patent office does to not tip competitors. Their previous patent applications I have read are specific about mechanism of actions, even on the website there are more hints:
MED3000 is a unique formulation of DermaSys® using volatile solvent components specifically tailored for the treatment of ED.
MED3000 is a treatment applied directly to the head (glans) of the ***** and massaged for 15 seconds. Patients or their partners can apply the gel directly to the man’s ***** as part of foreplay. It is fast-acting (60% of patients had onset of their erection within 5-10 minutes) and easy to use helping to restore spontaneity and intimacy in the relationship whilst offering an excellent safety profile.
So I doubt "mixture of herbs & spices"
"The compounds that comprise the formulation I assume must be novel...."
=======================================================
NDR50, I'm not sure if the compounds in the Dermasys (MED3000) formulation are 'novel' as such. MED3000 (as far as I'm aware) is the base 'formulation' of Dermasys (or a variant thereof). Usually the Dermasys base formulation is used to transport the active compound through the skin....but in MED3000's case there is no active compund. The exact mechanism for how MED3000 works hasn't been explained to us and I don't know if it is part of the patent application, possibky not. If the patent application is the same as MED2005 then the patent is for the 'formulation...a 'mixture of herbs & spices'. I don't know the level of protection that sort of patent provides...which could affect the value of the associated IP. I would expect a 'formulation' isn't the same as patenting a widget or 'novel' compound designed to do a specific task.
There is no doubt that pharmaceutical formulations can be patented. Dermasys as a formulation should warrant a patent extension due to its unique action in treating ED. The compounds that comprise the formulation I assume must be novel and will form the basis for any patent extension.